To overcome this, we have recently shown that TNBC primary tumour growth and, particularly, the metastatic spread, can be reduced in a bioengineered mouse model using drug-loaded pSiNPs targeting epidermal growth factor receptor (EGFR)—overexpressed in this BCa subtype—demonstrating the potential of pSiNPs as a drug delivery vector [15]. Here, EGFR is linked to neoplasm.